Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b/4 trial of ciraparantag (PER 977) as an investigational anticoagulant reversal agent

Next Previous
X
Search
Trial Profile

A Phase 3b/4 trial of ciraparantag (PER 977) as an investigational anticoagulant reversal agent

Status: Planning
Phase of Trial: Phase III/IV

Latest Information Update: 11 Aug 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Sponsors AMAG Pharmaceuticals; Perosphere

    • Most Recent Events

    • 06 Aug 2020 According to an AMAG Pharmaceuticals media release, Phase 3 clinical program of Ciraparantag (AMAG-977) would be conducted to support regulatory approval of ciraparantag by the U.S. Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare Products Regulatory Agency.
    • 17 Jan 2019 According to an AMAG Pharmaceuticals media release, company has completed the acquisition of Perosphere Pharmaceuticals.
    • 17 Jan 2019 According to an AMAG Pharmaceuticals media release, the company has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc.Through this acquisition, AMAG adds ciraparantag to its development portfolio.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top